Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

Clinical heterogeneity is a major barrier to effective treatment of chronic lymphocytic leukemia (CLL). Emerging evidence suggests that constitutive activation of various signaling pathways like mitogen-activated protein kinase–extracellular signal-regulated kinase (MAPK-Erk) signaling plays a role...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Shukla, Ashima, Rai, Karan, Shukla, Vipul, Chaturvedi, Nagendra K., Bociek, R. Gregory, Pirruccello, Samuel J., Band, Hamid, Lu, Runqing, Joshi, Shantaram S.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2016
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4865588/
https://ncbi.nlm.nih.gov/pubmed/26809508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-09-669317
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires